首页> 外文期刊>The Journal of Pathology: Clinical Research >The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study
【24h】

The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study

机译:骨骼外骨肉瘤的分子景观:临床病理和分子生物标志物研究

获取原文
       

摘要

Abstract Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing <5% of osteosarcomas and <1% of all soft-tissue sarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA and explore potential parameters that may affect outcome. Thirty-two cases were retrieved and histomorphology was reviewed. Clinical history and follow-up were obtained through electronic record review. DNA from formalin-fixed paraffin-embedded (FFPE) tissue was extracted and processed from 27 cases. Genome-wide DNA copy number (CN) alterations and allelic imbalances were analyzed by single nucleotide polymorphism array using Affymetrix OncoScan FFPE Assay. Massive high-throughput deep parallel sequencing was performed using a customized panel targeting 410 cancer genes. Log rank, Fisher's exact test and Cox proportional hazards were used for statistical analysis. In this series of 32 patients (male n = 12, female n = 20), the average age was 66 years (19?¢????93) and median follow up was 24 months (range 6?¢????120 months). Frequent genomic alterations included CN losses in tumour suppressor genes including CDKN2A (70%), TP53 (56%) and RB1 (49%). Mutations affecting methylation/demethylation, chromatin remodeling and WNT/SHH pathways were identified in 40%, 27%, and 27%, respectively. PIK3CA and TERT promoter variant mutations were identified in 11% of the cases. Cases harbouring simultaneous TP53 and RB1 biallelic CN losses were associated with worse overall survival and local recurrence ( p = 0.04, p = 0.02, respectively). CDKN2A losses and positive margins were also associated with worse overall survival ( p = 0.002; p = 0.03, respectively). Our findings suggest that age above 60, positive margin status, simultaneous biallelic TP53 and RB1 losses and CDKN2A loss are associated with a worse outcome in ESOSA. Comparison between conventional paediatric osteosarcoma and ESOSA shows that, while both share genetic similarities, there are notable dissimilarities and mechanistic differences in the molecular pathways involved in ESOSA.
机译:摘要骨骼外骨肉瘤(ESOSA)是一种罕见的软组织肿瘤,占骨肉瘤的<5%,占所有软组织肉瘤的<1%。本文中,我们调查了ESOSA的临床病理和分子特征,并探讨了可能影响结果的潜在参数。检索到32例并进行了组织形态学检查。通过电子记录审查获得临床病史和随访。从福尔马林固定石蜡包埋(FFPE)组织中提取DNA,并从27例病例中进行处理。使用Affymetrix OncoScan FFPE分析法通过单核苷酸多态性阵列分析全基因组DNA拷贝数(CN)改变和等位基因失衡。使用针对410个癌症基因的定制面板进行了大规模高通量深度平行测序。对数等级,Fisher精确检验和Cox比例风险用于统计分析。在这一系列的32例患者中(男性n = 12,女性n = 20),平均年龄为66岁(19岁93岁),中位随访时间为24个月(范围6岁)。 120个月)。常见的基因组改变包括肿瘤抑制基因中的CN丢失,包括CDKN2A(70%),TP53(56%)和RB1(49%)。分别影响40%,27%和27%的突变会影响甲基化/去甲基化,染色质重塑和WNT / SHH途径。在11%的病例中发现了PIK3CA和TERT启动子变异。 TP53和RB1双等位基因CN同时丢失的病例与较差的总生存率和局部复发有关(分别为p = 0.04,p = 0.02)。 CDKN2A丢失和阳性切缘也与较差的总体生存率相关(分别为p = 0.002; p = 0.03)。我们的发现表明,年龄超过60岁,边缘状态阳性,同时出现双等位基因TP53和RB1丢失以及CDKN2A丢失与ESOSA的预后较差有关。常规小儿骨肉瘤与ESOSA的比较表明,尽管两者均具有遗传相似性,但ESOSA涉及的分子途径存在显着的相似性和机制差异。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号